Satellite Bio is on a quest to create a better way to take on some of humankind’s most elusive diseases. It’s an audacious journey, and it’s led us to an entirely new category of regenerative medicine: Tissue Therapeutics. Tissue Therapeutics represents a revolutionary approach to using bioengineered tissues to assist organs affected by disease, and it lies at the heart of a future pipeline of cell-based treatments designed to tackle a broad range of severe, life-threatening conditions.
Location: United States, Massachusetts, Cambridge
Total raised: $110M
Investors 4
| Date | Name | Website |
| 23.04.2022 | Lightspeed... | lsvp.com |
| 20.01.2022 | aMoon Fund | amoon.fund... |
| - | S32 | s32.com |
| - | Catalio Ca... | cataliocap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.04.2022 | Seed | $110M | - |
Mentions in press and media 2
| Date | Title | Description |
| 21.04.2022 | Who is Chris Dixon? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Considering that Chris Dixon, 50, is one of the most well-known venture capitalists in the indust... |
| 20.04.2022 | Satellite Bio Raises USD110M In Seed and Series A Funding | Satellite Bio, a Cambridge, MA-based provider of tissue therapeutics, raised USD110M in Seed and Series A funding. The round was led by aMoon Growth, Lightspeed, aMoon Velocity, Polaris Partners and Polaris Innovation Fund, with participati... |